Basilicata Michele, Terrano Vincenzo, D'Aurelio Alessandro, Bruno Giovanni, Troiani Teresa, Bollero Patrizio, Napolitano Stefania
UOSD Special Care Dentistry, Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, 00133 Rome, Italy.
UniCamillus-Saint Camillus, International University of Health Sciences, 00131 Rome, Italy.
Healthcare (Basel). 2024 Jan 2;12(1):105. doi: 10.3390/healthcare12010105.
Melanoma cancer represents the most lethal type of skin cancer originating from the malignant transformation of melanocyte cells. Almost 50% of melanomas show the activation of BRAF mutations. The identification and characterization of BRAF mutations led to the development of specific drugs that radically changed the therapeutic approach to melanoma.
We conducted a narrative review of the literature according to a written protocol before conducting the study. This article is based on previously conducted studies. We identified articles by searching electronic databases (Medline, Google Scholar and PubMed). We used a combination of "melanoma", "Braf-Mek inhibitors", " targeted therapy" and "oral side effects".
Eighteen studies were reported in this article showing the relationship between the use of targeted therapy in melanoma cancer and the development of oral side effects, such as mucositis, hyperkeratosis and cellular proliferation.
Targeted therapy plays an important role in the treatment of melanoma cancer, showing a notable increase in response rate, prolonged progression-free survival and overall survival in BRAF-mutated melanoma patients. Oral side effects represent a common finding over the course of treatment. However, these adverse effects can be easily managed in a multidisciplinary approach involving collaboration between medical oncologists and dental doctors.
黑色素瘤是源自黑素细胞恶性转化的最致命的皮肤癌类型。几乎50%的黑色素瘤显示BRAF突变激活。BRAF突变的鉴定和特征分析促成了特定药物的开发，这些药物从根本上改变了黑色素瘤的治疗方法。
在开展本研究之前，我们根据书面方案对文献进行了叙述性综述。本文基于先前开展的研究。我们通过检索电子数据库（Medline、谷歌学术和PubMed）来确定文章。我们使用了“黑色素瘤”“BRAF - MEK抑制剂”“靶向治疗”和“口腔副作用”的组合词进行检索。
本文报道了18项研究，这些研究表明黑色素瘤靶向治疗的使用与口腔副作用（如黏膜炎、角化过度和细胞增殖）的发生之间的关系。
靶向治疗在黑色素瘤治疗中发挥着重要作用，在BRAF突变的黑色素瘤患者中显示出缓解率显著提高、无进展生存期和总生存期延长。口腔副作用是治疗过程中的常见现象。然而，通过肿瘤内科医生和牙科医生合作的多学科方法可以轻松管理这些不良反应。
